Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.66 |
| ▸ | EYA3 | Q99504 | 3/20 | 0.66 |
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31314642 | 0.88 | SIRT3 (0.64) | PTPN1EYA3TTRSIRT3NR1H4 | |
| SCHEMBL5987451 | 0.85 | SIRT3 (0.54) | PTPN1EYA3TTRSIRT3NR1H4 | |
| SCHEMBL3972664 | 0.85 | PTPN1 (0.70) | PTPN1EYA3SIRT3NR1H4THRA | |
| SCHEMBL5419199 | 0.84 | EYA3 (0.93) | PTPN1EYA3TTRSIRT3CYP2C9 | |
| SCHEMBL3972255 | 0.83 | PTPN1 (0.55) | PTPN1EYA3TTRSIRT3CYP2C9 | |
| SCHEMBL3968618 | 0.83 | SIRT3 (0.57) | PTPN1EYA3SIRT3NR1H4KDM5A | |
| SCHEMBL3970308 | 0.80 | PTPN1 (0.73) | PTPN1SIRT3 | |
| SCHEMBL5983412 | 0.80 | PTPN1 (0.73) | PTPN1SIRT3 | |
| SCHEMBL3971819 | 0.80 | SIRT3 (0.51) | PTPN1EYA3SIRT3NR1H4KDM5A | |
| SCHEMBL1287970 | 0.80 | EYA3 (1.00) | PTPN1EYA3TTRSIRT3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534894-B2 | Biphenyloxy-acids | WYETH (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1667959-A1 | BIPHENYLOXY-ACIDS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060020003-A1 | Biphenyloxy-acids | WYETH (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2005030702-A1 | BIPHENYLOXY-ACIDS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020003-A1 | Biphenyloxy-acids | AHR, ARNT, NR1H4 | PTPN1 1495/4885EYA3 1493/4885TTR 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.